Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 26;7(4):bvad013.
doi: 10.1210/jendso/bvad013. eCollection 2023 Feb 9.

The Eucalcemic Patient With Elevated Parathyroid Hormone Levels

Joseph L Shaker  1 , Robert A Wermers  2
Affiliations

The Eucalcemic Patient With Elevated Parathyroid Hormone Levels

Joseph L Shaker et al. J Endocr Soc. .

Abstract

Primary hyperparathyroidism (PHPT) is classically characterized by hypercalcemia with elevated or inappropriately normal parathyroid hormone (PTH) levels. Elevated PTH levels in the presence of normal calcium levels are not infrequently found during the evaluation of metabolic bone disorders or kidney stone disease. This can be caused by secondary hyperparathyroidism (SHPT) or normocalcemic primary hyperparathyroidism (NPHPT). NPHPT is due to autonomous parathyroid function whereas SHPT is caused by a physiologic stimulation to PTH secretion. Many medical conditions and medications can contribute to SHPT, and differentiation between SHPT and NPHPT may be difficult. Cases are presented to illustrate examples. In this paper, we review the distinction between SHPT and NPHPT as well as end organ effects of NPHPT and outcomes of surgery in NPHPT. We suggest that the diagnosis of NPHPT be made only after careful exclusion of causes of SHPT and consideration of medications that can increase PTH secretion. Further, we advise a conservative approach to surgery in NPHPT.

Keywords: hyperparathyroidism; normocalcemic primary hyperparathyroidism; primary hyperparathyroidism; secondary hyperparathyroidism.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Suggested approach to the eucalcemic patient with elevated parathyroid hormone levels.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122–1129. doi:10.1210/jc.2012-4022 - DOI - PMC - PubMed
    1. Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ III, Wermers RA. Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010). Bone. 2015;73:1–7. doi:10.1016/j.bone.2014.12.003 - DOI - PMC - PubMed
    1. Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J Bone Mineral Res. 2022;37(11):2293–2314. doi:10.1002/jbmr.4677 - DOI - PubMed
    1. El-Hajj Fuleihan G, Chakhtoura M, Cipriani C, et al. Classical and nonclassical manifestations of primary hyperparathyroidism. J Bone Mineral Res. 2022;37(11):2330–2350. doi:10.1002/jbmr.4679 - DOI - PubMed
    1. Buchebner D, Malmgren L, Christensson A, et al. Longitudinal assessment of PTH in community-dwelling older women—elevations are not associated with mortality. J Endocr Soc. 2017;1(6):615–624. doi:10.1210/js.2017-00104 - DOI - PMC - PubMed

LinkOut - more resources